<DOC>
	<DOCNO>NCT03023540</DOCNO>
	<brief_summary>All randomise patient Charcot-Marie-Tooth Type 1A ( CMT1A ) complete primary study CLN-PXT3003-02 , i.e . 15-month double-blind treatment PXT3003 placebo , eligible continue extension study CLN-PXT3003-03 . Patients randomise PXT3003 dose 1 2 primary study ( CLN-PXT3003-02 ) continue extension study dose , patient receive placebo assign one two active dos second randomization entry extension study .</brief_summary>
	<brief_title>Assessing Long Term Safety Tolerability PXT3003 Patients With Charcot-Marie-Tooth Disease Type 1A</brief_title>
	<detailed_description>PXT3003 rational design , fix combination low-dose ( RS ) baclofen , naltrexone hydrochloride D-sorbitol . The use PXT3003 multicenter , randomise , placebo control phase II study ( CLN-PXT3003-01 ) well-tolerated safe patient CMT1A three dose-levels investigate ( Attarian et al. , 2014 ) . The intermediate high dose PXT3003 demonstrate improvement disability patient population . Subsequently multicenter , randomise , placebo control phase III study ( CLN-PXT3003-02 ) ass efficacy safety PXT3003 treatment patient CMT1A initiate December 2015 . In March 2017 first patient complete 15-month treatment PXT3003 . Thereafter , patient allow entry extension study ( CLN-PXT3003-03 ) 9-month treatment PXT3003 . Thus patient initially randomise active treatment use PXT3003 24 month , whereas patient initially randomize inactive treatment use PXT3003 9 month .</detailed_description>
	<mesh_term>Tooth Diseases</mesh_term>
	<mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
	<mesh_term>Nerve Compression Syndromes</mesh_term>
	<mesh_term>Hereditary Sensory Motor Neuropathy</mesh_term>
	<criteria>Patients must complete 15 month doubleblind treatment primary study CLNPXT300302 , include procedure require Study Termination visit ( V6 ) Female patient must agree continue use approved method birth control throughout extension study Patients must sign write informed consent , specific extension study , order participate study . In case minor child age 16 18 year , parent ' child 's consent collect Any clinically significant change health status , opinion Investigator , would prevent subject participate study successfully complete study Any unauthorized concomitant treatment , study CLNPXT300302 ( e.g . include limited baclofen , naltrexone , sorbitol ( pharmaceutical form ) , opioids , levothyroxin , potentially neurotoxic drug amiodarone , chloroquine , cancer drug susceptible induce peripheral neuropathy )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Charcot Marie Tooth Type 1A</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>PXT3003</keyword>
</DOC>